It now includes oral GLP-1 drugs, amylin combinations, dual agonists, triple agonists, long-acting platforms, and differentiated assets designed for durability, tolerability, access, or broader metabolic indications
According to WHO and other researchers, if nothing is done to curb the problem, the global cost of overweight and obesity could potentially reach US$3 trillion per year by 2030 and more than US$18 trillion by 2060 (WHO 2024
The needles used are typically very fine (2932 gauge) and short (48 mm), designed specifically to reduce pain during subcutaneous administration
10.3390/molecules21030373 120 WeisM.MortensenS
semaglutide has more extensive cardiovascular outcome data Cardiovascular Disease: Semaglutide has proven heart benefits in SELECT trial Kidney Disease: Dosing adjustments may be needed for both Gastrointestinal Issues: Pre-existing GI problems may influence tolerance Lifestyle Factors: Neither medication works without lifestyle changes